Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab

References

• Rosenberg S A, Berard C W, Brown B W, Jr, Burke J, Dorfman R F, Glatstein E, et al. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(5 Suppl 5)75–88
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Armitage J O, Berg A R, Purtilo D T. Adult non-Hodgkin's lymphomas. Hematology: Clinical and Laboratory Practice, R L Bick, J M Bennett, R K Brynes, M J Cline, L Kass, G Murano, et al. CV Mosby Company, St Louis, MO 1993; 61:2: 875–893
   Google Scholar
• Gallagher C J, Gregory W M, Jones A E, Stansfeld A G, Richards M A, Dhaliwal H S, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Esteve J, López-Guillermo A, Martínez-Francés A, Bosch F, Terol M J, Campo E, et al. Presenting features, natural history, and prognostic factors in localized non-Hodgkin's lymphomas: analysis of 117 cases from a single institution. Eur J Haematol 1995; 55: 217–222
   PubMed Web of Science ®Google Scholar
• Bastion Y, Berger F, Bryon P A, Felman P, Ffrench M, Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2(Suppl 2)123–129
   PubMed Web of Science ®Google Scholar
• Romaguera J E, McLaughlin P, North L, Dixon D, Silvermintz K B, Garnsey L A, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991; 9: 762–769
   PubMed Web of Science ®Google Scholar
• López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriquez M A, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91: 2955–2960
   PubMed Web of Science ®Google Scholar
• Montoto S, López-Guillermo A, Ferrer A, Camós M, Alvarez-Larrán A, Bosch F, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002; 13: 523–530
   PubMed Web of Science ®Google Scholar
• Johnson P WM, Rohatiner A ZS, Whelan J S, Price C GA, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147
   PubMed Web of Science ®Google Scholar
• Shipp M A, Harrington D P, Anderson J R, Armitage J O, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• López-Guillermo A, Montserrat E, Bosch F, Terol M J, Campo E, Rozman C. Applicability of the International Index for Aggressive Lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–1348
   PubMed Web of Science ®Google Scholar
• Foussard C, Desablens B, Sensebe L, François S, Milpied N, Deconinck E, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicablity to stage III-IV patients. Ann Oncol 1997; 8(Suppl 1)49–52
   PubMed Web of Science ®Google Scholar
• Reff M E, Carner K, Chambers K S, Chinn P C, Leonard J E, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445
   PubMed Web of Science ®Google Scholar
• Grillo-López A J, White C A, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26(5 Suppl 14)66–73
   PubMed Web of Science ®Google Scholar
• Piro L D, White C A, Grillo-López A J, Janakiraman N, Saven A, Beck T M, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655–661
   PubMed Web of Science ®Google Scholar
• Davis T A, Grillo-López A J, White C A, McLaughlin P, Czuczman M S, Link B K, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143
   PubMed Web of Science ®Google Scholar
• Davis T A, White C A, Grillo-López A J, Velásquez W S, Link B, Maloney D G, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–1857
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Vose J M, Link B K, Grossbard M L, Czuczman M, Grillo-López A, Gilman P, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López A J, White C A, Czuczman M, Maloney D, Alkuzweny B, et al. Prognostic factors for non-Hodgkin's lymphoma (NHL) patients treated with chemotherapy (CRX) may not predict response duration in patients treated with immunotherapy: rituximab experience. Am Assoc Canc Res 1999; 40: 718(#4746)
   Google Scholar
• McLaughlin P, Grillo-López A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Grillo-López A J, Lee D, Alkuzweny B, Shen D, Nasizadeh H. Clinical activity of rituximab in patients who have relapsed following ABMT. Proc Am Soc Clin Oncol 2000; 19: 23a(#18)
   Google Scholar
• Grillo-López A J. Rituximab: an insider's historical perspective. Semin Oncol 2000; 27(6 Suppl 12)9–16
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J KC, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Grillo-López A J. Rituximab (Rituxan®/MabThera®): the first decade (1993 – 2003). Expert Rev Anticancer Ther 2003; 3: 767–779
   PubMedGoogle Scholar
• Grillo-López A J, Cheson B D, Horning S J, Peterson B A, Carter W D, Varns C L, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol 2000; 11: 399–408
   PubMed Web of Science ®Google Scholar
• SAS. SAS/STAT User's Guide, version 6, 4th edn. SAS Institute, Inc., Cary, NC 1990
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 456–481
   Web of Science ®Google Scholar
• Hermans J, Krol A DG, van Groningen K, Kluin P M, Kluin-Nelemans J C, Kramer M HH. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460–1463
   PubMed Web of Science ®Google Scholar
• Bastion Y, Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients?. J Clin Oncol 1994; 12: 1340–1342
   PubMed Web of Science ®Google Scholar
• Foran J M, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11(Suppl 1)S117–S121
   PubMed Web of Science ®Google Scholar
• Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13: 928–943
   PubMed Web of Science ®Google Scholar
• Yunis J J, Oken M M, Kaplan M E, Ensrud K M, Howe R R, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982; 307: 1231–1236
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-López A J, McLaughlin P, White C A, Saleh M, Gordon L, et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001; 12: 109–114
   PubMed Web of Science ®Google Scholar
• Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29(1 Suppl 2)56–69
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
   PubMed Web of Science ®Google Scholar
• Ferraris A M, Giuntini P, Gaetana G F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 1979; 54: 928–932
   PubMed Web of Science ®Google Scholar
• Grillo-López A J. A model for the breadth and depth of clinical effect observed with rituximab and Zevalin in NHL patients. Blood 2002; 100: 310b
   Web of Science ®Google Scholar